Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer
June 25, 2013 at 07:04 AM EDT
Seattle Genetics, Inc. (NASDAQ: SGEN ) today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC
